* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Document
Gluten immunochemistry wikipedia , lookup
Hygiene hypothesis wikipedia , lookup
Immune system wikipedia , lookup
Anti-nuclear antibody wikipedia , lookup
Rheumatoid arthritis wikipedia , lookup
Immunocontraception wikipedia , lookup
Molecular mimicry wikipedia , lookup
Innate immune system wikipedia , lookup
Adaptive immune system wikipedia , lookup
DNA vaccination wikipedia , lookup
Ciclosporin wikipedia , lookup
Multiple sclerosis research wikipedia , lookup
Adoptive cell transfer wikipedia , lookup
Psychoneuroimmunology wikipedia , lookup
X-linked severe combined immunodeficiency wikipedia , lookup
Polyclonal B cell response wikipedia , lookup
Cancer immunotherapy wikipedia , lookup
FUN2: 11:00-12:00 Scribe: Ryan O’Neill Friday, December 5, 2008 Proof: Caitlin Cox Dr. King Immunopharmacological Agents Page 1 of 5 IL-2 – Interleukin 2, CSA – cyclosporine, MPA - mycophenolic acid I. Outline [S2] a. Immune Response b. Immunosuppressants c. Immunostimulants II. The Immune System [S3] a. Overall goal of immune system is to distinguish self from “nonself.” b. Innate Immunity - what we are born with, also called non-specific immunity. i. Initiates and activates the response to an offending agent. c. Adaptive Immunity i. Creates a response that specifically neutralizes or kills that agent. ii. 2 Major Mechanisms of Adaptive Immunity 1. Cell mediated (cytotoxicity) immunity 2. Humoral (antibody) immunity iii. Cytokines have a vital role in initiation and regulation of both immune responses. III. Simplified Schematic of Immune Response [S4] a. Helps illustrate the immune system. b. Both humoral and cellular immunity work by identifying the Ag as part of a bacteria or virus. c. In humoral immunity the B cell matures into a plasma cell, which secretes Abs and binds to Ag and identifies it for destruction. d. T cell matures into an active-killer T cell and the T cell binds to Ags on surface cell and helper T cells secrete Interleukin which promote the growth of both B and T cells. IV. General Principles Regarding Immunosuppression[S5] a. Primary immune response is more easily suppressed than secondary (once memory has been established therapy will only have modest effects). b. Immunosuppressants have different effects on different immune reactions so the dose required to inhibit the immune response to one Ag may differ from another. c. Suppression more likely if therapy begins before exposure to immunogen; however, most immune disorders are treated after auto-immunity has been established. V. Clinical Indications for Use of Immunosuppressive Therapy [S6] a. Treatment of Organ Transplantation i. Liver ii. Heart iii. Kidney b. Treatment of autoimmune disorders VI. 5 Classes of Immunosuppressive Agents [S7] a. T-cell blockers b. Glucocorticoids c. Cytotoxic Drugs d. Antibody Reagents e. Cytokine Inhibitors VII. T-cell blockers Cyclosporine and Tacrolimus [S8] a. Cyclosporine & Tacrolimus b. Chemistry i. Cyclic polypeptide derived from a fungus. c. Mechanism of Action i. Inhibits lymphocytic proliferation by binding to cyclophilin. ii. Cyclosporine-cyclophilin complex inhibits calcineurin. d. Tacrolimus Chemistry i. Tacrolimus also inhibits calcineurin, but it is a macrolide antibiotic. e. Mechanism of Action i. Binds to FK506 binding protein. ii. Tacrolimus-FK506 complex inhibits calcineurin. VIII. Cyclosporine and Tacrolimus [S9] a. When calcineurin is inhibited, then you have prevention of dephosphorylation of nuclear factor of activated Tcells. You also have inhibition of T-cell receptor-activated induction of IL-2. b. Calcineurin inhibits the IL-2 induction by cyclosporine (CsA) binding to the cyclophilin (CpN) and FK506 binding to a binding protein. That inhibits calcineurin and calcineurin is just a step in the pathway that inhibits the induction of IL-2 and others like 3 and 4 and TNF- gene. FUN2: 11:00-12:00 Scribe: Ryan O’Neill Friday, December 5, 2008 Proof: Caitlin Cox Dr. King Immunopharmacological Agents Page 2 of 5 IX. Cyclosporine [S10] a. Dosage Forms i. Intravenously ii. Orally (2 formulations) 1. Soft gelatin capsules 2. Microemulsion formulation - higher F (bioavailability) and Cmax (max concentration after dose). iii. Available as eye drops: The drug Restasis is cyclosporine and it restores tear production. b. Toxicity i. Oral and IV forms are cause nephrotoxicity and can cause hypertension. c. Pharmacology i. Extensive metabolism in gut and liver (CYP 450 3A4). ii. Excreted in the bile. iii. Significant drug interactions, we common measure drug concentrations in transplant patients. d. Therapeutic Uses i. Kidney, heart, liver transplant ii. Rheumatoid Arthritis iii. Psoriasis iv. And dry eyes if you are using the Restasis form. X. Tacrolimus (Prograf, FK506) [S11] a. Dosage Forms i. Intravenously ii. Orally iii. 10-100x more potent than cyclosporine in its ability to inhibit IL-2. b. Toxicity i. Nephrotoxicity ii. Neurotoxicity iii. Hypertension iv. Hyperglycemia c. Pharmacology i. Metabolized by liver CYP 450 3A4 (so we have to measure drug concentration). d. Therapeutic Uses i. Used predominantly in transplant patients. ii. Hepatic Transplantation iii. Kidney Transplantation iv. Therapeutic Drug Monitoring 1. Drugs that have a narrow therapeutic index where the concentrations that are required to be effective are close to the concentrations that cause toxicity, those are the ones that we measure and monitor. XI. T-cell blockers Sirolimus (Rapamune) [S12] a. Chemistry i. Antifungal agent formerly known as rapamycin. b. Mechanism of Action i. Similar to the other two agents (CSA and FK506), but not a calcineurin inhibitor. ii. Inhibits intracellular signal pathway from the IL-2 receptor to DNA synthesis. iii. Less effective inhibitor of cytokine synthesis than CSA, but just as potent at preventing the proliferation of T-cells and B-cells. c. Pharmacology i. CYP 450 mediated metabolism. d. Therapeutic Uses i. Indicated for acute renal rejection in combination with cyclosporine and steroids. e. Toxicities i. Leukopenia, thrombocytopenia ii. Hypertriglyceridemia iii. Less renal toxicity compared to CSA and Tacrolimus, possibly due to lack of calcineurin inhibition. XII. Corticosteroids [S13] Just a brief review, will see it again later a. Mechanism of Action i. Reduces circulation of lymphocytes ii. Inhibits antibody formation and binding to target cells iii. Anti-inflammatory properties FUN2: 11:00-12:00 Scribe: Ryan O’Neill Friday, December 5, 2008 Proof: Caitlin Cox Dr. King Immunopharmacological Agents Page 3 of 5 iv. Prevents B and T-cell proliferation b. Pharmacology i. Rapidly removed from blood and distributed to muscles, liver, skin and intestines. ii. Prednisolone is the biologically active preparation, but is converted in the body to other forms. iii. Short half-life, but its capacity to inhibit lymphokine production persists for 24 hours. c. Therapeutic Uses i. Combination therapy with other immunosuppressive agents d. Toxicities i. Increase of incidence of infections ii. Impaired growth, bone disease, diabetes and obesity iii. Taper dose to prevent acute adrenal insufficiency XIII. Cytotoxic Drugs - Azathioprine (Imuran) [S14] a. Mechanism of action i. Pro-drug metabolized to 6-mercaptopurine (6-MP) which antagonizes purine metabolism thus preventing DNA synthesis and T-cell proliferation. b. Pharmacology i. Half-life is short, in minutes, but pharmacodynamic impact on inhibition of purine synthesis persists for days. ii. Dose is decreased in hepatic dysfunction because you have reduced conversion to the active 6-MP. iii. Accumulation of metabolites in renal insufficiency causing pancytopenia (decrease dose). c. Drug Interactions i. If azathioprine is given with allopurinol (an agent used for gout) it inhibits xanthine oxidase. 1. XO inactivates 6-MP → Increased 6-MP levels and pancytopenia d. Therapeutic Uses i. Renal Transplantation--effective for prevention of acute rejection (not treatment). ii. Rheumatoid Arthritis e. Toxicities i. Bone marrow suppression, neoplasia, irreversible liver damage XIV. Cytotoxic Drugs Mycophenylate Mofetil (CellCept) [S15] a. Mechanism of Action i. Prodrug of mycophenolic acid (MPA) ii. Inhibits inosine monophosphate dehydrogenase → depletes endogenous purine nucleotide pools, which leads to inhibition of de novo purine biosynthesis. iii. Slows T and B cell growth. b. Pharmacology i. Hydrolyzed by the liver after GI absorption. It is hydrolyzed to MPA, which undergoes glucuronidation. ii. Goes back through the liver known as enterohepatic circulation, which converts inactive metabolite back to active MPA. c. Therapeutic Uses i. Renal and cardiac transplantation (with steroids and cyclosporine) d. Drug Interactions i. Tacrolimus ii. Antacids iii. Ganciclovir e. Toxicities i. Gastrointestinal, hematologic and increased risk of infections XV. Cytotoxic Drugs - Cyclophosphamide (Cytoxan) [S16] a. Mechanism of action i. Nitrogen mustard derivative ii. Interferes with DNA replication and transcription of RNA. b. Therapeutic Uses i. Rejection following renal, liver, heart, and bone marrow transplants ii. Possibly as effective as azathioprine for maintenance of renal transplants and better for liver transplants. c. Toxicities i. Bone marrow suppression ii. Incidence of neoplasms, specifically bladder cancer, which is thought to be due to one of the metabolites – acrolein. XVI. Antibody Reagents Immunoglobulins [S17] a. Antibodies against human lymphocytes or their surface protein can have significant immunosuppressant action. FUN2: 11:00-12:00 Scribe: Ryan O’Neill Friday, December 5, 2008 Proof: Caitlin Cox Dr. King Immunopharmacological Agents Page 4 of 5 b. Two types: Polyclonal and Monoclonal antibodies. c. Polyclonal antibodies i. Polyclonal antibodies are non-specific. ii. Binds to protein on the surface of lymphocyte triggering the complement response and subsequently lysis of the lymphocyte. iii. Essentially targets all T-cells which results in a broad immunosuppression that can lead to infection, so again, it is non-specific. d. The two main agents that are polyclonal antibodies are Thymoglobulin and ATGAM. e. Antilymphocyte immunoglobulin (Thymoglobulin) i. Derived from rabbits f. Antithymocyte immunoglobulin (ATGAM) i. Derived from horses XVII. Antibody Reagents Immunoglobulins [S18] a. Polyclonal antibodies (cont.) i. Pharmacology—must be administered IV. 1. Bind to circulating lymphocytes, bone marrow cells, and visceral tissues, but do not distribute into lymphoid tissues (spleen, lymph nodes). ii. Clinical Notes 1. Efficacy varies from batch to batch which creates a significant risk for allergic reaction, mainly this occurs because the drugs are derived from animals. 2. Duration of therapy: 7 to 14 days 3. ASE: Fever, chills, N/V (nausea/vomiting), anaphylactic reaction (rare) and serum sickness XVIII. Antibody Reagents Immunoglobulins [S19] a. Monoclonal antibodies i. Process by which large quantities of antibodies (targeted against a particular antigen-specific) can be produced. ii. OKT3 & Anti-CD25 monoclonal antibodies will be discussed 1. Basiliximab 2. Daclizumab XIX. Antibody Reagents Immunoglobulins [S20] a. This picture helps explain how monoclonal antibodies are produced. b. Top left hand corner: Mouse immunized by injecting antigen X, which stimulates antibodies against the antigen. c. Antibody forming cells are isolated from the mouse's spleen. d. Monoclonal antibodies produced by fusing single antibody-forming cells to tumor cells grown in culture which results in a hybridoma. e. Each hybridoma produces large quantities of identical antibody molecules. f. Once a monoclonal antibody is made, it can be used as a specific probe to track down and purify the specific protein. XX. Antibody Reagents Murine Monoclonal Antibody (Orthoclone, OKT3) [S21] a. 3 types that we are going to discuss. The first is OKT3. b. Mechanism of action i. Is a murine (mouse IgG2a immunoglobulin) binds to the CD3 antigen of human T cells. ii. Reverses graft rejection most probably by blocking the function of all T cells which play a major role in acute rejection. c. Pharmacology i. IV administration d. Toxicities i. Cytokine-release syndrome (higher frequency after first and second doses). ii. Flu-like symptoms iii. CNS symptoms iv. Acute reversible renal dysfunction e. Therapeutic Uses i. The steroid methylprednisolone is given 1- 4 hours prior to the first dose to decrease the incidence and severity of reaction. XXI. Antibody Reagents Daclizumab (Zenapax) [S22] a. Mechanism of Action i. It is a monoclonal antibody-recombinant DNA technology that contains 90% human and 10% murine antibody sequences. ii. Binds to the -subunit of the IL-2 receptor expressed only on the surface of activated lymphocytes FUN2: 11:00-12:00 Scribe: Ryan O’Neill Friday, December 5, 2008 Proof: Caitlin Cox Dr. King Immunopharmacological Agents Page 5 of 5 iii. Thus, it is an IL-2 receptor antagonist that inhibits IL-2 binding, which is important for the activation of T cells in the acute rejection process. b. Pharmacology i. IV administration only; has fairly long half-life. ii. The pharmacodynamic effect is long; it lasts for 120 days. c. Therapeutic Uses i. Indicated for the prophylaxis to prevent the transplant rejections in combination with other drugs. d. Has a few side effects listed. XXII. Antibody Reagents Basiliximab (Simulect) [S23] a. Mechanism of Action i. Same mechanism of action. It also contains human and murine (produced by human and murine antibodies). b. Pharmacology i. Intravenous administration ii. Shorter half-life, but is still relatively long. c. Therapeutic Uses i. Indicated for prophylaxis. d. Toxicities i. Minor toxicities of hypersensitivity reactions. XXIII. Cytokine Inhibition [S24] a. Specifically talk about TNF-α and IL inhibitor. b. For the sake of time, read the slide. (This is what she said.) XXIV. Cytokine Inhibitor Etanercept (Enbrel) [S25] a. Mechanism of Action i. Binds to tumor necrosis factor alpha (TNF) and TNF. ii. Prevents TNF from binding with its receptors thus preventing all of the other activities. b. Pharmacology i. Subcutaneous injection twice weekly. c. Therapeutic Uses i. Rheumatoid Arthritis, Crohn’s Disease d. Has a few toxicities listed. XXV. Cytokine Inhibitor Infliximab (Remicade) [S26] a. Mechanism of Action i. Binds to TNF ii. Read the rest of the slide on your own. XXVI. General Principles Regarding Immunostimulation [S27] a. Most of these drugs are used for: i. AIDS ii. Chronic infectious diseases iii. Cancers XXVII. Intravenous Immune Globulins [S28] a. You would think an increase in the immune system would have benefits. b. IV IGs are pooled plasma from donors. c. IM or IV administration; very long half-life. d. Specific preparations also available i. Hepatitis B, botulism, diptheria, tetanus, rabies e. Allergic reactions: anaphylaxis (biggest side effect) XXVIII. Cytokines as Immunostimulants [S29] a. Interferon (alpha, beta and gamma) i. γ-1b prevention of infections in chronic granulomatous disease ii. α iii. β b. Interleukin-2 i. Stimulates T-helper and T cytotoxic cells ii. Metastatic melanoma and renal cell carcinoma [end 17 min]